{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1032.61",
  "meta" : {
    "versionId" : "9",
    "lastUpdated" : "2018-05-09T01:07:38.000-04:00"
  },
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.61",
  "version" : "20180509",
  "name" : "Immunotherapy",
  "status" : "active",
  "date" : "2018-05-09T01:00:04-04:00",
  "publisher" : "MITRE Steward",
  "compose" : {
    "include" : [{
      "system" : "http://www.icd10data.com/icd10pcs",
      "version" : "2023",
      "concept" : [{
        "code" : "XW03351",
        "display" : "Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"
      },
      {
        "code" : "XW033C3",
        "display" : "Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"
      },
      {
        "code" : "XW04351",
        "display" : "Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"
      },
      {
        "code" : "XW043C3",
        "display" : "Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"
      }]
    }]
  },
  "expansion" : {
    "identifier" : "urn:uuid:d475cfae-d5fc-445c-b893-7e93339480b2",
    "timestamp" : "2022-09-27T21:43:34-04:00",
    "total" : 0,
    "offset" : 0,
    "parameter" : [{
      "name" : "count",
      "valueInteger" : 1000
    },
    {
      "name" : "offset",
      "valueInteger" : 0
    }]
  }
}